Top Five Takeaways From Bayer Consumer Health's 2022 Results

 
• By Tom Gallen
  
Generate a summary of this article
Listen to this article
Beta

Beating global market growth, continuing macroeconomic headwinds and spin-off perspectives were among the key talking points as Bayer Consumer Health reported its 2022 sales and earnings.

Bayer AG, German multinational pharmaceutical and life sciences company, one of largest pharmaceutical companies in world, brand logo on its office building located in Lyon, France - February 23, 2020

Bayer Consumer Health beat the market in 2022 as a combination of rising prices (+6.2%) and higher volumes (+2.2%) helped currency and portfolio adjusted sales to increase by 8.4% to €6.08bn ($6.47bn). The German firm outstripped the global consumer health market growth rate of 8% in 2022, as it recorded a notable jump in demand for cough and cold and digestive health products.

Broad-based growth across all regions and categories helped Bayer to outperform its 2022 sales guidance of 6-7%. Europe/Middle East/Africa adjusted...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

SpotifyApple PodcastsWebsite

More from Europe

EU JCA: Milestone Report Shows Room For Improvement For Orphan Drugs And PICOs

In a major milestone for the EU’s pricing and reimbursement landscape, the European Commission has published the first ever, much anticipated, joint clinical assessment report.

Over The Counter: Exploring The Postbiotic Opportunity In Consumer Health, With Kerry’s Sonja Nodland

 
• By David Ridley

In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry. 

Marinomed Starts Restructuring Proceedings As Debts Mount

 
• By Tom Gallen

Weak demand for virus-blocking nasal sprays since the pandemic has left Austrian biotech Marinomed with mounting debts. The company has applied for restructuring proceedings with an Austrian court in an attempt to secure its future.

Perrigo Adds High-Strength Paracetamol To UK Solpadeine Line

 
• By David Ridley

Perrigo aims its new SolpaOne high-strength paracetamol effervescent at UK pharmacists, who now have expanded powers as part of the UK government's Pharmacy First initiative. 

More from Geography

Perrigo Securities Class-Action Settlement Awards Attorneys’ Fees, Expenses Lower Than Requested

 
• By Malcolm Spicer

Court order dismisses claims against Perrigo and Joseph Papa, its former CEO, with prejudice. Settlement also bars any claim against plaintiffs and class members, “whether arising under state, federal, common or foreign law,” alleging liability for losses.

Over The Counter: Exploring The Postbiotic Opportunity In Consumer Health, With Kerry’s Sonja Nodland

 
• By David Ridley

In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry. 

US FDA Adcomm Reform Ideas: Neutral Facilitator As Chair, Public Hearing Lottery Process Tweaks

 
• By Sue Sutter

Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.